Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Sarcopenia from mechanism to diagnosis and treatment in liver disease
Figure 2 Inflammatory pathways affecting hepatic insulin resistance
Lipids in Liver Disease: Looking Beyond Steatosis
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
The inflammasome in liver disease
Figure 1 Pathophysiological aspects of insulin
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 47, Issue 1, Pages (July 2007)
Volume 52, Issue 3, Pages (March 2010)
Volume 142, Issue 6, Pages (May 2012)
Uncoupling proteins and non-alcoholic fatty liver disease
Nonalcoholic steatohepatitis
Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology 
IL-6 pathway in the liver: From physiopathology to therapy
Volume 56, Issue 4, Pages (April 2012)
Omega 3 – Omega 6: What is right for the liver?
Volume 40, Issue 3, Pages (March 2004)
NASH: a mitochondrial disease
Volume 11, Issue 5, Pages (May 2010)
ChREBP in NASH – A liver transcription factor comes in from the cold
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Volume 62, Issue 1, Pages (January 2015)
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk  Jennifer H. Stern, Joseph M. Rutkowski,
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Guido T. Bommer, Ormond A. MacDougald  Cell Metabolism 
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Inflammation and intracellular metabolism: new targets in OA
IKKɛ: A Bridge between Obesity and Inflammation
Volume 57, Issue 5, Pages (November 2012)
Selective Insulin and Leptin Resistance in Metabolic Disorders
Nat. Rev. Endocrinol. doi: /nrendo
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
“De-liver-ance” From CB1: A Way to Counteract Insulin Resistance?
The genetics of alcohol dependence and alcohol-related liver disease
Volume 69, Issue 4, Pages (October 2018)
Innate sensors of pathogen and stress: Linking inflammation to obesity
Volume 140, Issue 6, Pages (March 2010)
Konstantinos G. Michalakis, M.D., James H. Segars, M.D. 
Cannabinoid signaling and liver therapeutics
Herbert Tilg, Gökhan S. Hotamisligil  Gastroenterology 
Pierre Theurey, Jennifer Rieusset  Trends in Endocrinology & Metabolism 
Banking on ATM as a new target in metabolic syndrome
Varman T. Samuel, Gerald I. Shulman  Cell Metabolism 
p38δ and PKD1: Kinase Switches for Insulin Secretion
NASH animal models: Are we there yet?
Signalling links in the liver: Knitting SOCS with fat and inflammation
Insulin Resistance in the Defense against Obesity
Volume 61, Issue 6, Pages (December 2014)
The impact of intestinal microflora on serum bilirubin levels
Toshimasa Yamauchi, Takashi Kadowaki  Cell Metabolism 
Lipids in Liver Disease: Looking Beyond Steatosis
Volume 62, Issue 3, Pages (March 2015)
Autophagy in liver diseases: Time for translation?
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease  Michal Pawlak,
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Pathogenesis of cholestatic hepatitis C
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Foxa1 and Foxa2 regulate bile duct development in mice
Lipid Sensing and Insulin Resistance in the Brain
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
Macrophages, Immunity, and Metabolic Disease
C16:0-Ceramide Signals Insulin Resistance
NF-κB, Inflammation, and Metabolic Disease
Presentation transcript:

Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?  Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology  Volume 44, Issue 2, Pages 253-261 (February 2006) DOI: 10.1016/j.jhep.2005.11.030 Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Causes of hepatic insulin resistance. Obesity induces sub-acute inflammation that promotes insulin resistance by increasing hepatic SOCS expression (via IL-6). SOCS inhibits insulin signalling directly by competing for phosphorylation sites on the insulin receptor, and indirectly by inducing SREBP-1c. In turn, SREBP-1c suppresses IRS2 synthesis, and increases fatty acid synthesis. Hepatic levels of fatty acyl-CoA increase in response to serum NEFA (fatty acids arriving from peripheral lipolysis), dietary intake and endogenous fatty acid synthesis, or from impaired β-oxidation (possibly the result of mitochondrial injury). This increase in fatty acyl-CoA (and possibly other lipid metabolites) activates PKC-θ to catalyse serine/threonine phosphorylation of the IRS proteins, and/or IKK-β to activate NF-κB with release of IL-6 and augmentation of SOCS induction. [This figure appears in colour on the web.] Journal of Hepatology 2006 44, 253-261DOI: (10.1016/j.jhep.2005.11.030) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Hepatic lipid homeostasis. Lipid homeostasis is achieved by balancing fatty acid synthesis with fatty acid oxidation and export. Fatty acid synthesis is induced by insulin and glucose via the transcription factors SREBP-1c and ChREBP, respectively. LXR also promotes fatty acid synthesis by inducing SREBP-1c. Fatty acid oxidation is promoted by PPAR-α and the protein kinase, AMPK. Adiponectin, an adipocytokine, increases hepatic fatty acid oxidation by inducing PPAR-α and AMPK; increased levels of hepatic fatty acids also induce PPAR-α. PPAR-α and LXR have opposite functions but their engagement of the same heteropartner, RXR, enables hepatocytes to transiently commit to either fatty acid synthesis or fatty acid oxidation. [This figure appears in colour on the web.] Journal of Hepatology 2006 44, 253-261DOI: (10.1016/j.jhep.2005.11.030) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions